FOXO4-DRI Purity: HPLC & MS Verification
Maintaining strict analytical validation standards is paramount when evaluating novel D-retro-inverso peptides in cellular senescence and apoptosis research. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) verification ensure that investigators receive FOXO4-DRI with verified structural integrity and an absence of truncation artifacts. PX1 Research supplies laboratory-grade FOXO4-DRI accompanied by lot-specific Certificates of Analysis to eliminate experimental confounding in cell culture and preclinical models.
Quick answer
Maintaining strict analytical validation standards is paramount when evaluating novel D-retro-inverso peptides in cellular senescence and apoptosis research. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) verification ensure that investigators receive FOXO4-DRI with verified structural integrity and an absence of truncation artifacts. PX1 Research supplies laboratory-grade FOXO4-DRI accompanied by lot-specific Certificates of Analysis to eliminate experimental confounding in cell culture and preclinical models.
Key takeaways
- FOXO4-DRI is a synthetic D-retro-inverso peptide engineered to disrupt the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein.
- The primary sequence of FOXO4-DRI is synthesized using D-amino acids arranged in reverse sequence relative to the native L-amino acid binding domain of FOXO4.
- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the primary analytical tool for determining the chemical purity of FOXO4-DRI.
- While RP-HPLC establishes chromatographic homogeneity, Mass Spectrometry (MS) provides exact molecular weight confirmation to verify sequence identity.
Introduction to FOXO4-DRI in Cellular Senescence Research
FOXO4-DRI is a synthetic D-retro-inverso peptide engineered to disrupt the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein. In senescent cells, FOXO4 sequesters p53 within the nucleus, preventing p53 from initiating apoptotic signaling cascades. By competitively binding to FOXO4, the peptide liberates p53, allowing it to translocate to the mitochondria and trigger targeted apoptosis in senescent cell populations.
Because FOXO4-DRI targets specific protein-protein interaction domains, experimental reproducibility hinges entirely on chemical purity and conformational fidelity. Researchers utilizing FOXO4-DRI in cell culture assays or animal models require absolute assurance that batch-to-batch variations do not alter binding affinities or introduce toxic impurities. Accessing comprehensive data through our research library hub allows principal investigators to contextualize analytical parameters prior to initiating in vitro protocols.
Chemical Structure & The Complexity of D-Retro-Inverso Synthesis
The primary sequence of FOXO4-DRI is synthesized using D-amino acids arranged in reverse sequence relative to the native L-amino acid binding domain of FOXO4. This retro-inverso design preserves the side-chain spatial topology necessary for p53 binding while rendering the peptide resistant to endogenous proteolytic degradation by peptidases and proteases.
However, solid-phase peptide synthesis (SPPS) of D-retro-inverso sequences presents unique chemical challenges. The coupling efficiency of D-amino acids can vary due to steric hindrance and altered reaction kinetics during chain elongation. These factors elevate the risk of deletion sequences, incomplete coupling events, and residual racemization. Consequently, rigorous analytical evaluation is required to confirm that the synthesized material contains the full-length target sequence rather than a mixture of closely related side products.
HPLC Verification: Quantifying Chromatographic Purity
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the primary analytical tool for determining the chemical purity of FOXO4-DRI. The technique separates the primary peptide sequence from synthesis artifacts, truncated fragments, and organic contaminants based on hydrophobic interactions with a stationary phase (typically a C18 silica column).
During HPLC analysis, a mobile phase gradient comprising water, acetonitrile, and ion-pairing reagents such as trifluoroacetic acid (TFA) is applied. Ultraviolet (UV) detection at 214 nm (peptide backbone absorption) and 280 nm (aromatic side-chain absorption) generates a chromatogram. Area-under-the-curve (AUC) integration measures the target peak relative to total detected peaks. Superior foxo4-dri purity exhibits a single, sharp chromatogram peak with minimal baseline drift or shoulder peaks, indicating a pure research compound suitable for precise quantitative assays.
Mass Spectrometry Validation: Confirming Molecular Identity
While RP-HPLC establishes chromatographic homogeneity, Mass Spectrometry (MS) provides exact molecular weight confirmation to verify sequence identity. Methods such as Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) ionize the FOXO4-DRI sample, measuring the mass-to-charge ratio (m/z) of the resulting ions.
Because deletion sequences (missing a single D-amino acid residue) may co-elute with the target peptide during HPLC under certain conditions, MS is essential to detect subtle molecular weight discrepancies. High-resolution mass spectrometry confirms that the observed monoisotopic or average mass aligns precisely with the theoretical molecular mass of FOXO4-DRI. This verification guarantees that experimental effects observed in vitro are attributable exclusively to the intended peptide motif.
Endotoxin Testing & Bio-Burden Standards in Cell Assays
In cell culture and preclinical rodent studies, bacterial endotoxins (lipopolysaccharides, or LPS) present a serious risk of experimental confounding. Endotoxins trigger toll-like receptor 4 (TLR4) signaling in immune and non-immune cells, inducing inflammatory cytokine release, altered cell viability, and non-specific apoptosis. These off-target inflammatory pathways can obscure or misrepresent senolytic mechanism data.
PX1 Research conducts quantitative Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays on every lot of FOXO4-DRI. By enforcing strict endotoxin limits (<0.01 EU/mg to <0.1 EU/mg), laboratory researchers can isolate specific FOXO4-p53 pathway dynamics without interference from bacterial contaminants or background immune activation.
Why >99% FOXO4-DRI Purity Matters for Reproducible Research
Using lower-purity peptides (e.g., <90% or <95%) introduces unquantified variables into laboratory experiments. Synthetic impurities—such as diastereomers, truncated sequences, and residual protecting groups—can act as competitive inhibitors or non-specific cellular toxins. In quantitative assays designed to measure IC50 values, caspase-3/7 activation, or senescence-associated beta-galactosidase (SA-β-gal) expression, impure reagents distort dose-response curves.
Achieving >99% purity ensures that the observed biological activity correlates directly with the calculated molarity of FOXO4-DRI added to the test system. For academic laboratories, biotechnology firms, and core facilities ordering via wholesale lab accounts, batch-to-batch consistency eliminates the costly need to re-validate baseline assays when transitioning between reagent lots.
Comparative Overview: FOXO4-DRI and Related Longevity Research Compounds
Preclinical investigation into cellular aging, metabolic stress, and mitochondrial dysfunction often evaluates FOXO4-DRI alongside other targeted peptides. While FOXO4-DRI operates specifically via nuclear p53 liberation and targeted senolysis, compounds such as /product/ss-31 focus on mitochondrial inner-membrane cardiolipin stabilization to reduce reactive oxygen species (ROS) production. Similarly, /product/mots-c functions as a mitochondrial-derived peptide influencing metabolic homeostasis and AMPK pathway activation, whereas /product/epithalon is investigated for its role in telomerase activation and transcriptional regulation.
Understanding these mechanistic distinctions allows investigators to construct multi-target in vitro models. However, comparing results across different compound classes requires that each peptide—whether a D-retro-inverso structure like FOXO4-DRI or a mitochondrial peptide—adheres to identical standards of HPLC/MS verification and low endotoxin thresholds.
PX1 Research Quality Assurance: USA Synthesis & ISO 17025 Testing
PX1 Research maintains rigorous quality control frameworks tailored to institutional research demands. All FOXO4-DRI batches are synthesized within cGMP-compliant facilities using advanced solid-phase peptide synthesis methodologies. Following synthesis and purification, independent ISO 17025 accredited laboratories perform HPLC and Mass Spectrometry testing to verify purity percentages and molecular mass.
Every shipment includes a lot-specific Certificate of Analysis detailing raw HPLC integration data, mass spectra, net peptide content, and endotoxin assay results. To review analytical documentation formats before ordering, researchers can consult our comprehensive Certificate of Analysis guide. All compounds are stored under climate-controlled conditions and dispatched same-day (M–F) from distribution hubs in California and Arizona.
Reconstitution and Laboratory Handling Guidelines
FOXO4-DRI is supplied as a lyophilized powder for enhanced chemical stability during storage and transport. To preserve structural integrity prior to assay execution, primary containers should be stored at -20°C or -80°C. Before reconstitution, vials must be allowed to equilibrate to room temperature inside a desiccator to prevent moisture condensation on the lyophilized cake.
Reconstitution protocols typically utilize sterile, bacteriostatic water or buffered solutions such as phosphate-buffered saline (PBS, pH 7.4). For assays requiring higher working concentrations, sterile DMSO may be used as a primary solvent before diluting into culture media. Repeated freeze-thaw cycles must be avoided by aliquoting reconstituted solutions into working volumes, following standard lyophilized peptide storage guidelines.
Frequently Asked Questions
What analytical methods are used to verify FOXO4-DRI purity?
FOXO4-DRI purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity and area-under-the-curve quantification, combined with Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF to confirm exact molecular mass.
Why is D-retro-inverso peptide synthesis prone to specific impurities?
D-retro-inverso peptides utilize D-amino acids in reverse sequence, which exhibit different coupling kinetics and steric hindrance during solid-phase synthesis compared to L-amino acids. This increases the likelihood of deletion sequences or incomplete couplings, requiring high-resolution HPLC purification.
What endotoxin levels are acceptable for in vitro FOXO4-DRI assays?
For sensitive cell culture and apoptosis assays, endotoxin levels should ideally remain below 0.1 EU/mg, with premium research lots testing under 0.01 EU/mg, preventing non-specific TLR4 pathway activation.
How does PX1 Research guarantee lot-to-lot consistency?
PX1 Research subjects every synthesized lot of FOXO4-DRI to independent, third-party testing at ISO 17025 accredited laboratories in the USA. Full HPLC chromatograms, mass spectra, and endotoxin data are published per lot.
What solvent should be used to reconstitute FOXO4-DRI for lab experiments?
Reconstitution is commonly performed using sterile laboratory-grade water or PBS (pH 7.4). For high-concentration stock solutions, low-percentage DMSO can be utilized prior to serial dilution in cell culture media.
What is the shelf life of lyophilized FOXO4-DRI?
Lyophilized FOXO4-DRI stored at -20°C or -80°C remains stable for up to 24 months. Once reconstituted, solution aliquots should be used promptly or frozen at -80°C to minimize degradation.
What is the difference between peak purity percentage and net peptide content?
Peak purity percentage (measured by HPLC) represents the ratio of target FOXO4-DRI to synthetic peptide impurities. Net peptide content measures the total percentage of actual peptide weight relative to counterions (e.g., acetate or TFA) and residual moisture.
Is FOXO4-DRI available for institutional bulk ordering?
Yes, PX1 Research provides institutional accounts and bulk procurement options with batch-matched COAs through our wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.